# Molecular Signatures and Network Alterations Underlying GBM Progression and Recurrence

**Authors:** Andrea Pop Crisan, Cristina Ciocan, Radu Pirlog, Alexandru Necula, Darius Adin Al Hajjar, Lavinia-Lorena Pruteanu, Constantin-Ioan Busuioc, Deo Prakash Pandey, Aurel George Mohan, Cornelia Braicu, Ioana Berindan-Neagoe

PMC · DOI: 10.3390/medicina62020336 · 2026-02-06

## TL;DR

This study identifies gene-expression patterns and molecular networks linked to glioblastoma progression and recurrence, offering insights into potential therapeutic targets.

## Contribution

The study introduces composite Tumor and Recurrence Scores to classify GBM states and reveals novel gene-expression signatures associated with tumor recurrence.

## Key findings

- Distinct molecular signatures were identified in primary and recurrent GBM samples.
- Transcriptomic analysis revealed four tumor states: normal-like, proliferative, transitional, and recurrence-adapted.
- Dysregulated genes were linked to cellular growth, proliferation, and movement pathways.

## Abstract

Background and Objectives: Glioblastoma (GBM) is the most aggressive form of primary brain tumor, characterised by high recurrence rates and poor patient prognosis. This study aimed to identify gene-expression signatures and molecular networks associated with primary and recurrent GBM to better understand the biological mechanisms underlying tumor progression. Materials and Methods: Gene expression analysis of TCGA data was conducted to identify differentially expressed genes across tumor, recurrent, and normal brain tissues. Analysis of overlapping differentially expressed gene sets revealed both common and specific gene-expression profiles across the groups, highlighting genes potentially involved in GBM recurrence. Gene network and canonical pathway analyses were performed using Ingenuity Pathway Analysis (IPA) to identify key pathways and cellular functions altered in GBM. Results: Our data identified distinct molecular signatures in tumor, recurrent, and normal brain samples, highlighting dysregulated genes associated with cellular growth, proliferation, and movement. Transcriptomic stratification revealed progressive tumor- and recurrence-adapted states, with composite Tumor Scores (TS) and Recurrence Scores (RS) classifying samples into four classes: normal-like, proliferative, transitional, and recurrence-adapted tumor states. Conclusions: These findings provide insights into the signaling networks and biological mechanisms underlying GBM recurrence and may guide the identification of potential therapeutic targets to improve the management of this malignancy.

## Linked entities

- **Diseases:** Glioblastoma (MONDO:0018177), brain tumor (MONDO:0021211)

## Full-text entities

- **Genes:** COL3A1 (collagen type III alpha 1 chain) [NCBI Gene 1281] {aka EDS4A, EDSVASC, PMGEDSV}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, IGFBP2 (insulin like growth factor binding protein 2) [NCBI Gene 3485] {aka IBP2, IGF-BP53}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, BIRC5 (baculoviral IAP repeat containing 5) [NCBI Gene 332] {aka API4, EPR-1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, SOX2 (SRY-box transcription factor 2) [NCBI Gene 6657] {aka ANOP3, MCOPS3}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, HLA-DRA (major histocompatibility complex, class II, DR alpha) [NCBI Gene 3122] {aka HLA-DRA1}, MKI67 (marker of proliferation Ki-67) [NCBI Gene 4288] {aka KIA, MIB-, MIB-1, PPP1R105}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, POSTN (periostin) [NCBI Gene 10631] {aka OSF-2, OSF2, PDLPOSTN, PN}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, NNMT (nicotinamide N-methyltransferase) [NCBI Gene 4837], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}
- **Diseases:** Primary (MESH:D010538), endocrine and neurological disorders (MESH:D004700), Organismal Injury and Abnormalities (MESH:D000014), brain tumor (MESH:D001932), GBM (MESH:D005909), Cancer (MESH:D009369), malignant gliomas (MESH:D005910), inflammatory (MESH:D007249), injury to (MESH:D014947), RS (MESH:D012008), Neurological Diseases (MESH:D020271), tumorigenesis (MESH:D063646)
- **Chemicals:** temozolomide (MESH:D000077204), calcium (MESH:D002118)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941869/full.md

---
Source: https://tomesphere.com/paper/PMC12941869